Abstract
Background: Melasma can be recalcitrant to treatment, and relapses are common. Pycnogenol has been reported to be effective in treating melasma.Objective: To compare the efficacy, safety and tolerability of 75 mg pycnogenol taken orally twice a day vs. a placebo, in association with the triple combination and broad‐spectrum sunscreen for the treatment of facial melasma.Methods: A randomized, double‐blind, parallel, placebo‐controlled study was conducted on 44 women with facial melasma in a single centre from May 2019 through November 2019. Patients with melasma were randomly assigned to orally take 75 mg pycnogenol (PYC) or a placebo (PLAC) twice a day for 60 days. Both groups also received tinted sunscreen [Sun Protection Factor (SPF) 50; Persistent Pigment Darkening (PPD) 17] for daytime use and a topical triple combination at bedtime. The primary outcome was a change from the baseline Modified Melasma Area Severity Index (mMASI) score. Secondary outcomes were improvements in the patients' quality of life (MELASQoL), colorimetric indices and Global Aesthetic Improvement Scale (GAIS).Results: All participants completed the trial. The mean (SD) age of the participants was 39 (7) years, and 91% were phototypes III–IV. Both groups exhibited a reduction in mMASI scores, MELASQoL scores and colour contrast (P < 0.01). The mean (CI 95%) reductions of the mMASI scores were 49% (36–61%) for PYC and 34% (16–47%) for PLAC. The reductions in mMASI scores and colorimetric contrast were superior for the PYC group (P < 0.05). The analysis of GAIS resulted in an improvement of 86% (CI 95%: 68–96%) for the participants in the PYC group and 55% (CI 95%: 32–73%) for those in the PLAC group. There were no adverse effects related to oral treatment.Conclusion: Pycnogenol is well‐tolerated and increases the effectiveness of broad‐spectrum sunscreen and the triple combination in the treatment of facial melasma in women.

This publication has 42 references indexed in Scilit: